Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - bikalutamid - tablett, filmdrasjert - 50 mg

Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - bikalutamid - tablett, filmdrasjert - 150 mg

Norge - norsk - Statens legemiddelverk

teva sweden ab - bikalutamid - tablett, filmdrasjert - 150 mg

Norge - norsk - Statens legemiddelverk

teva sweden ab - bikalutamid - tablett, filmdrasjert - 50 mg

Norge - norsk - Statens legemiddelverk

laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 150 mg

Norge - norsk - Statens legemiddelverk

laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 50 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Norge - norsk - Statens legemiddelverk

orifarm as - bikalutamid - tablett, filmdrasjert - 50 mg

Norge - norsk - Statens legemiddelverk

orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg

Norge - norsk - Statens legemiddelverk

orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg